相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1901
进行中（未招募）
1
100.0%
暂无批准数据
- IASO Bio has signed a technology licensing agreement with Instituto Butantan to develop CAR-T cell therapy for hematological cancer in Brazil, targeting patients who have not responded to conventional treatments. - The partnership aims to significantly reduce treatment costs from up to $500,000 per patient by manufacturing through a public institution, potentially enabling future incorporation into Brazil's Unified Health System. - Local development will occur at the Advanced Therapies Center of São Paulo, marking a milestone for Brazilian science in making cutting-edge cell therapies accessible through public healthcare. - The collaboration represents IASO Bio's strategic expansion into Latin America, combining their proprietary cell therapy technology with Butantan's manufacturing capabilities as Brazil's largest vaccine and serum producer.
- Replicate Bioscience and Instituto Butantan announced a collaboration agreement granting exclusive rights to develop and commercialize the novel srRNA rabies vaccine RBI-4000 in Brazil and Latin America. - Phase 1 clinical trials demonstrated RBI-4000's high therapeutic index with durable bioactivity at low doses and mild to moderate reactogenicity compared to other RNA-based vaccine technologies. - Instituto Butantan will fund registrational clinical trials for both post-exposure and pre-exposure prophylaxis while Replicate retains global rights outside Latin America and receives tiered royalties. - The partnership aims to address rabies, a deadly disease with 99% mortality rate causing 59,000 deaths annually, while improving cold chain storage and thermostability advantages over conventional vaccines.
- Mabloc and Instituto Butantan announced a strategic partnership to co-develop MBL-YFV-01, a breakthrough monoclonal antibody therapy for yellow fever virus infection, addressing an urgent unmet medical need. - Primate studies published in Science Translational Medicine showed a single 50mg/kg dose of MBL-YFV-01 fully controlled viremia and prevented severe disease and death in 100% of treated primates. - The partnership comes amid escalating yellow fever outbreaks in Brazil, with confirmed human cases in São Paulo, Minas Gerais, and Espírito Santo, where millions remain at risk despite vaccine availability. - Instituto Butantan will manufacture MBL-YFV-01 and lead clinical studies to support regulatory submission to ANVISA, potentially delivering one of the world's first post-exposure therapies for yellow fever.
- A randomized, double-blind Phase II trial of NestaCell® demonstrated significant improvements in motor function scores compared to placebo in 35 Huntington's disease patients over 10 months. - Both tested doses (1 and 2 million cells/kg) showed statistically significant benefits on the primary endpoint UHDRS-TMS, with the higher dose also improving functional capacity measures. - The therapy exhibited a favorable safety profile with only mild treatment-related adverse events including hair changes and phlebitis, supporting advancement to Phase III trials.
